RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Denali Therapeutics Stock

Denali Therapeutics P/S 2024

Denali Therapeutics P/S

130.7

Ticker

DNLI

ISIN

US24823R1059

WKN

A2H9G8

As of Sep 28, 2024, Denali Therapeutics's P/S ratio stood at 130.7, a 917.12% change from the 12.85 P/S ratio recorded in the previous year.

The Denali Therapeutics P/S history

Denali Therapeutics Aktienanalyse

What does Denali Therapeutics do?

Denali Therapeutics Inc is a biotechnology company specializing in the research and development of therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2015 by four former employees of Genentech, with the goal of finding innovative treatments for serious neurological conditions. Denali Therapeutics' business model is based on a patented platform technology that allows the company to target and deliver its drugs precisely to the brain of patients. The company utilizes "liposomes," microscopic bubbles of fat that are loaded with the drug and then transported to the brain through the bloodstream. Denali Therapeutics is divided into three divisions: development platform, therapy development, and diagnosis development. The development platform is the core business of Denali Therapeutics. Here, the company continues to develop its liposome technology to be used for various neurological diseases. The therapy development focuses on developing targeted drugs for specific neurodegenerative diseases. Denali Therapeutics collaborates closely with neurologists and other experts to develop the best possible therapies for patients. The diagnosis development aims to detect early symptoms of neurodegenerative diseases, enabling early diagnosis and treatment. Denali Therapeutics is primarily working on the development of testing methods that will allow for early detection of Alzheimer's and Parkinson's. Currently, Denali Therapeutics has several promising drugs in its pipeline. One of the most important projects is a drug for Alzheimer's disease, which is currently being tested in clinical trials. The drug targets the accumulation of beta-amyloid, which is responsible for the progression of the disease. Another promising project is a drug for Parkinson's, which is also being tested in clinical trials. The drug targets the accumulation of alpha-synuclein, a protein implicated in the development of Parkinson's. Denali Therapeutics aims to develop new therapies for neurodegenerative diseases to improve the lives of patients. The company is committed to answering the many unanswered medical questions in the field of neurology and making a contribution to overcoming these serious diseases. Denali Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Denali Therapeutics's P/S Ratio

Denali Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Denali Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Denali Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Denali Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Denali Therapeutics stock

What is the price-to-earnings ratio of Denali Therapeutics?

The price-earnings ratio of Denali Therapeutics is currently 130.7.

How has the price-earnings ratio of Denali Therapeutics changed compared to last year?

The price-to-earnings ratio of Denali Therapeutics has increased by 917.12% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Denali Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Denali Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Denali Therapeutics affect the company?

An increase in the price-earnings ratio of Denali Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Denali Therapeutics affect the company?

A decrease in the price-earnings ratio of Denali Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Denali Therapeutics?

Some factors that influence the price-earnings ratio of Denali Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Denali Therapeutics pay?

Over the past 12 months, Denali Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Denali Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Denali Therapeutics?

The current dividend yield of Denali Therapeutics is .

When does Denali Therapeutics pay dividends?

Denali Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Denali Therapeutics?

Denali Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Denali Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Denali Therapeutics located?

Denali Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Denali Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Denali Therapeutics from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did Denali Therapeutics pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of Denali Therapeutics in the year 2023?

In the year 2023, Denali Therapeutics distributed 0 USD as dividends.

In which currency does Denali Therapeutics pay out the dividend?

The dividends of Denali Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Denali Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Denali Therapeutics

Our stock analysis for Denali Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Denali Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.